Recruiting A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT06500702 Conditions Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +10 more Locations Investigational Site Number : 8400007 — Birmingham, Alabama, United States Investigational Site Number : 8400015 — Orange, California, United States Investigational Site Number : 8400012 — San Francisco, California, United States Investigational Site Number : 8400025 — Tampa, Florida, United States View all 71 locations View more locations Show fewer locations Loading locations... View Trial Details
